Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial
Public ClinicalTrials.gov record NCT06980025. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Dose Escalation Study of Low Dose Aspirin for the Prevention of Recurrent Preterm Birth
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth at less than 35 weeks gestation who are randomized to either 162 mg aspirin or 81 mg aspirin daily. The study drug will be initiated between 10 and 15 weeks gestation and continued through 36 weeks, 6 days gestation. The primary endpoint is recurrent preterm delivery or fetal death prior to 35 weeks, 0 days gestation.
Study identification
- NCT ID
- NCT06980025
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,800 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 14 Years and older
- Sex
- Female
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2025
- Primary completion
- Dec 30, 2028
- Completion
- Feb 27, 2029
- Last update posted
- Apr 8, 2026
2025 – 2029
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama - Birmingham | Birmingham | Alabama | 35233 | Recruiting |
| Regents of the University of California San Francisco | San Francisco | California | 94143 | Recruiting |
| Northwestern University | Chicago | Illinois | 60611 | Recruiting |
| Columbia University | New York | New York | 10032 | Recruiting |
| University of North Carolina - Chapel Hill | Chapel Hill | North Carolina | 27599 | Recruiting |
| Duke University | Durham | North Carolina | 27710 | Recruiting |
| Case Western Reserve University | Cleveland | Ohio | 44109 | Recruiting |
| Ohio State University | Columbus | Ohio | 43210 | Recruiting |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Magee Women's Hospital of UPMC | Pittsburgh | Pennsylvania | 15213 | Recruiting |
| Brown University | Providence | Rhode Island | 02905 | Recruiting |
| Baylor College of Medicine | Houston | Texas | 77030 | Recruiting |
| University of Texas - Houston | Houston | Texas | 77030 | Recruiting |
| University of Utah Medical Center | Salt Lake City | Utah | 84132 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06980025, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06980025 live on ClinicalTrials.gov.